Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns) -- Ignore unavailable to you. Want to Upgrade?

To: Bilow who wrote (92)	6/8/1998 1:06:00 PM
From: Anthony Wong	Respond to of 228

Bilow, here are the recent analyst upgrades/downgrades from Bloomberg (hey, the target price ain't so bad even after the downgrade). I still trying to figure it out about the off-label use. Pathogenesis Corp. Reiterated 'Buy' at Prudential Bloomberg News June 4, 1998, 12:29 p.m. PT Princeton, New Jersey, June 4 (Bloomberg Data) -- Pathogenesis Corp. (PGNS US) was reiterated ''buy'' by analyst David Lippman at Prudential Securities. The 12-month target price is $56.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652 PathoGenesis Corp. Cut to 'Outperform' at Warburg Dillon Read Bloomberg News June 4, 1998, 1:13 p.m. PT Princeton, New Jersey, June 4 (Bloomberg Data) -- PathoGenesis Corp. (PGNS US) was downgraded to ''outperform'' from ''buy'' by analyst David Webber at SBC Warburg Dillon Read Inc. The 12 to 18-month target price is $ 42 per share. -- Colleen Sferra in Princeton, New Jersey, (609)279-3843